Introduction: Idiopathic facial aseptic granuloma (IFAG) is an uncommon granulomatous lesion associated with childhood rosacea. Affected children often experience recurrent eyelid chalazia. Objectives: We present a single-center retrospective study of 16 cases of IFAG in order to assess their clinical course and discuss any therapeutic intervention. Methods: Children presenting with facial lesions persisting for at least six weeks which exhibited clinical features of an (IFAG) were included in the study. Results: There were 10 females and six males, with a mean age of 6.4 (± 4) years. The mean time from the onset of treatment to complete resolution of lesions was 11 months for the children treated with a topical regimen and 7.2 months for those children treated with both topical and systemic antibiotics respectively (P<0.005). Ultrasound examination revealed a solid, hypoechoic lesion with increased perilesional or intralesional blood flow in the hypodermis without any calcium deposit as an early finding. Skin biopsies were performed in seven children. Recurrent chalazia were reported in all 16 cases. Conclusions: IFAG is a benign lesion that may persist for several months before resolution. Ultrasound examination is a valuable tool for establishing a diagnosis. Clinicians should monitor children with IFAG for potential ocular complications that may arise later in life.
Introduction: Nail psoriasis significantly impairs quality of life and remains therapeutically challenging due to the limited efficacy of treatments. Objectives: To compare the clinical efficacy and safety of Nd:YAG laser and intense pulsed light (IPL) therapy in nail psoriasis using total and modified NAPSI scores, clinical and dermatoscopic findings. Methods: This retrospective study evaluated 101 nails from 14 patients treated with either IPL (N=66) or Nd:YAG laser (N=35). Treatments were administered every 4–6 weeks for 2–8 sessions. Nail psoriasis severity was assessed at baseline and at six months using NAPSI, mNAPSI, and dermatoscopic and clinical features. Results: PL therapy significantly reduced matrix (3.48→1.94), nail bed (3.47→1.33), total NAPSI (6.95→3.27), and mNAPSI (9.21→3.92) scores (P<0.05). Nd:YAG laser treatment also resulted in significant improvements in matrix (3.54→2.20), nail bed (3.77→1.97), total NAPSI (7.31→4.17), and mNAPSI (8.83→5.23) scores (P<0.05). In our cohort, IPL appeared to have a more favorable impact on mNAPSI, pitting, salmon patches, subungual hyperkeratosis, and splinter hemorrhages, while Nd:YAG tended to provide greater improvement in leukonychia (P<0.05). No recurrence or adverse event was observed during the 12-month follow-up period. Conclusions: Both IPL and Nd:YAG laser therapies are safe and effective options for nail psoriasis. IPL showed superior efficacy in nail bed involvement, whereas Nd:YAG may be preferred for leukonychia. Laser-based treatments are promising alternatives in refractory cases.
Introduction: Nonmelanoma skin cancer (NMSC), mainly including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is the most often diagnosed malignancy worldwide, frequently necessitating substantial healthcare resources due to its elevated incidence and recurrence rates. Objective: This study evaluated a combined procedure of curettage and carbon dots-photodynamic therapy (CDs-PDT) to treat skin cancer superficial BCC (S-BCC), nodular BCC (N-BCC), invasive microglandular BCC (IMG-BCC), solid surface extension BCC (SS-BCC), and in situ SCC (Bowen). Methods: Twenty-two patients (15 male and 7 female) with 27 lesions were treated with this combined procedure. In all cases, curettage was performed first, followed by CDs-PDT. Previously, CDs had been used as cream or hydrogel vehicles for photodynamic treatment. PDT was administered in four or eight sessions, depending on each patient's response. The results indicate that PDT-based cream/CDs achieved complete responses in S-BCC, N-BCC, and SS-BCC and partial responses in the elimination of Bowen's lesions. PDT-based hydrogel-cream/CDs showed partial responses in S-BCC and SS-BCC. Results: This research found, for the first time, that PDT-based cream/CDs have better results than hydrogel-cream/CDs for the treatment of nonmelanoma skin cancers BCC and Bowen disease. Rapid healing was noted following each PDT session-based CD, and no pain was reported during irradiation. Conclusion: These results indicate that CD-based PDT could be used in the clinical setting for the treatment of non-melanoma skin cancer.
INTRODUCTION:Acne vulgaris is a prevalent skin disorder, especially among adolescents. While topical retinoid and benzoyl peroxide (BPO) are standard treatments, their side effects often decrease patient adherence. OBJECTIVES:This study aimed to explore the efficacy and safety of topical N-acetylcysteine (NAC) plus doxycycline compared to BPO-doxycycline in moderate acne vulgaris. METHOD:In this double-blind randomized clinical trial, 40 patients were allocated into one of two groups: Group A received 100 mg/day doxycycline+5% NAC, while Group B received 100 mg/day doxycycline +5% BPO. Patients were assessed over three months using total lesion count (TLC), Investigator Global Assessment (IGA), Global Acne Grading System (GAGS), and Cardiff Acne Disability Index (CADI). Statistical analysis was performed using STATA 14.2, with P<0.05 considered significant. RESULTS:In comparison with BPO, NAC treatment led to a significantly greater improvement in CADI scores (MD=-3.60, 95% CI: -4.26 - -2.95, P<0.001), GAGS scores (MD = -9.76, 95% CI: -11.84 - -7.68, P<0.001), TLC (MD = -4.29, 95% CI: -6.38 - -2.19, P=0.002), inflammatory lesion count (MD = -2.93, 95% CI: -5.18 - -0.68, P=0.003), and IGA scores (MD = -0.85, 95% CI: -1.12 - -0.58, P<0.001). Repeated mixed measures ANOVA further confirmed significant between-group differences in GAGS scores at the second and third months of patients' follow-up. Only one patient reported mild scaling with receiving NAC. CONCLUSION:Topical NAC combined with doxycycline was significantly more effective than BPO-doxycycline in acne treatment, with minimal adverse effects. These results indicate that NAC may serve as an acceptable alternative for the treatment of moderate acne vulgaris.
Introduction: Psoriasis, a chronic inflammatory skin condition, affects 125 million worldwide. Current treatments provide symptomatic relief but face limitations. Guselkumab shows promise for moderate-to-severe psoriasis. Objective: We aimed to conduct a systematic review and meta-analysis exploring the safety and efficacy of guselkumab in moderate-to-severe psoriasis. Methods: We searched PubMed, EMBASE, and Cochrane Library for randomized controlled trials (RCTs) comparing guselkumab to placebo in moderate-to-severe psoriasis. Primary endpoints: Investigators’ Global Assessment (IGA) 0, Psoriasis Area and Severity Index (PASI) 90, and ≥1 adverse event (AE). Secondary endpoints: IGA 0/1, PASI75, PASI100, Dermatology Life Quality Index (DLQI), and ≥1 severe AE. RStudio was used for statistical analyses. Results: We included 1607 patients from 6 RCTs. Guselkumab significantly increased odds of IGA 0 (odds ratio (OR) OR: 73.87; 95%confidence interval (CI): 32.53-167.73; P<0.00001; I2=0.0%), and IGA 0/1 (OR: 54.84; 95% CI: 24.72–121.64; P<0.00001; I2=60.1%). Also, the OR of PASI75 (OR: 58.42; 95% CI: 23.03–148.17; P<0.001; I2=70.0%), PASI90 (OR: 46.47; 95% CI: 14.23–151.76; P<0.001; I2=71.7%), and PASI100 (OR: 59.27; 95% CI: 23.17–151.61; P<0.001; I2=0.0%) were higher with guselkumab. DLQI change was greater with guselkumab (MD: -8.46; 95% CI: -10.31 – -6.62; P<0.01; I²=77.8%). No significant difference in AEs and severe AEs between guselkumab and placebo (OR: 0.92; 95% CI: 0.68–1.24; P=0.58; I²=30.9%), (OR: 1.19; 95% CI: 0.54–2.64; P=0.66; I²=0.0%). Leave-one-out analysis identified PROTOSTAR as a source of heterogeneity. Subgroup analysis showed higher IGA 0 and PASI90 ORs in adults than in adolescents/children, with no dosage-based differences in PASI90 or AE. Conclusion: This meta-analysis suggests that guselkumab does significantly improve moderate-to-severe psoriasis, without a significant increase in AEs.
Citation: Moscardi A, Tartaglia J, Ciolfi C, Alaibac M. Type C Lymphomatoid Papulosis Following Immune Checkpoint Inhibition in a Melanoma Patient: A Reactive Mimicker of Cutaneous CD30+ Lymphoma.. Dermatol Pract Concept. 2026;16(2):6772. DOI: https://doi. Copyright: (c) 2026 Moscardi et al. This is an open-access article distributed under the terms of the Creative Commons Attributiondistribution, and reproduction in any medium, provided the original authors and source are credited. Authorship: All authors have contributed significantly to this publication.
Introduction: Bullous pemphigoid (BP) is the most common autoimmune blistering disorder, with anti-BP180 antibodies playing a key role in its pathogenesis and diagnosis. However, their utility in disease monitoring remains debated. Objectives: This study evaluate the role of anti-BP180 antibody monitoring in BP management through a single-center retrospective analysis and literature review. Methods: We analyzed 149 BP patients diagnosed between 2014 and 2024 at the Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna. Anti-BP180 titers were measured at baseline, six months, and remission. Therapeutic responses and antibody dynamics were assessed and compared with the literature. Results: Higher baseline anti-BP180 levels correlated with severe disease and prolonged remission times. A ≥60% reduction in titers was associated with successful therapeutic tapering and lower relapse rates. Patients with secondary BP forms exhibited lower baseline titers and faster remission. Conclusions: Anti-BP180 monitoring serves as a valuable adjunct to clinical assessment, aiding therapeutic decisions, particularly in determining tapering timelines. Nonetheless, integrated approaches combining serological and clinical evaluations remain essential.
Introduction: The increasing popularity of tattoos has been paralleled by a rise in tattoo-related skin reactions. Among these, tattoo-induced cutaneous lymphoid hyperplasia (CLH) remains a rare but increasingly recognized complication. Its pathogenesis and incidence are not yet fully understood, and diagnosis relies on histopathological confirmation via skin biopsy. Treatment approaches include topical or intralesional corticosteroids, surgical excision, and ablative CO₂ laser therapy in refractory cases. Objectives: To analyze and describe the clinical and histopathological features of tattoo-induced CLH, including patient demographics, tattoo characteristics (e.g., location, ink color), latency periods, and lymphocyte predominance. Methods: This study presents a case series of 15 patients with histologically-confirmed tattoo-induced CLH observed at dermatology departments in Brescia, Italy, and Gdańsk, Poland, between May 2017 and June 2023. These cases were integrated with a comprehensive literature review, resulting in a total of 58 patients analyzed. Data collected included patient demographics, tattoo location, latency period between tattooing and lesion onset, clinical features, ink color involved, lymphocyte predominance on histology, treatment modalities, and outcomes. The median patient age was 39 years, with an average latency of 33 months. Results: Red ink was the most frequently implicated pigment. The predominant histopathological pattern was T-cell infiltration. Treatment responses varied. While topical and intralesional steroids showed inconsistent efficacy, surgical excision and ablative CO₂ laser treatments yielded the most favorable and sustained outcomes. Conclusions: These findings underscore the importance of recognizing CLH as a delayed immune-mediated reaction, particularly to red pigments. Accurate diagnosis through biopsy is essential to distinguishing CLH from other tattoo-related dermatoses or cutaneous lymphomas, guiding appropriate management strategies.
